Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DF9001 |
| Synonyms | |
| Therapy Description |
DF9001 is a tri-specific natural killer cell engager therapy that binds to tumor-expressed EGFR and NK cells, potentially inducing an anti-tumor immune response against EGFR-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DF9001 | DF-9001|DF 9001 | DF9001 is a tri-specific natural killer cell engager therapy that binds to tumor-expressed EGFR and NK cells, potentially inducing an anti-tumor immune response against EGFR-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05597839 | Phase Ib/II | DF9001 DF9001 + Pembrolizumab | Study of DF9001 in Patients With Advanced Solid Tumors | Completed | USA | 0 |